scispace - formally typeset
Search or ask a question
Institution

I.M. Sechenov First Moscow State Medical University

EducationMoscow, Russia
About: I.M. Sechenov First Moscow State Medical University is a education organization based out in Moscow, Russia. It is known for research contribution in the topics: Medicine & Population. The organization has 7984 authors who have published 9355 publications receiving 68997 citations.
Topics: Medicine, Population, Cancer, Disease, Blood pressure


Papers
More filters
Journal ArticleDOI
12 Oct 2020
TL;DR: Five enigmatic conditions, including sarcoidosis, Sjögren’s syndrome, undifferentiated connective tissue disease, silicone implant incompatibility syndrome (SIIS), and immune-related adverse events (irAEs), are defined as classical examples of ASIA.
Abstract: Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was first introduced in 2011 by Shoenfeld et al. and encompasses a cluster of related immune mediated diseases, which develop among genetically prone individuals as a result of adjuvant agent exposure. Since the recognition of ASIA syndrome, more than 4400 documented cases have been reported so far, illustrated by heterogeneous clinical manifestations and severity. In this review, five enigmatic conditions, including sarcoidosis, Sjogren’s syndrome, undifferentiated connective tissue disease, silicone implant incompatibility syndrome (SIIS), and immune-related adverse events (irAEs), are defined as classical examples of ASIA. Certainly, these disorders have been described after an adjuvant stimulus (silicone implantation, drugs, infections, metals, vaccines, etc.) among genetically predisposed individuals (mainly the HLA-DRB1 and PTPN22 gene), which induce an hyperstimulation of the immune system resulting in the production of autoantibodies, eventually leading to the development of autoimmune diseases. Circulating autonomic autoantibodies in the sera of patients with silicone breast implants, as well as anatomopathological aspects of small fiber neuropathy in their skin biopsies have been recently described. To our knowledge, these novel insights serve as a common explanation to the non-specific clinical manifestations reported in patients with ASIA, leading to the redefinition of the ASIA syndrome diagnostic criteria.

39 citations

Journal ArticleDOI
TL;DR: This review attempted to determine the current status of the databases PubMed and Scopus to investigate the medicinal plants possessing anti-atherosclerotic activity in experimental and clinical studies.
Abstract: Atherosclerosis is a chronic multifactorial disease characterized by mainly changes of blood lipids profile and inflammation in vessel wall. The cardiovascular disease based on atherosclerosis is currently the leading cause of mortality in developed countries. Therefore, timely prevention and therapy of atherosclerosis are able to reduce the risk of the development of its clinical manifestations. Anti-atherosclerotic activity of medicinal plants mainly appears in their multiple effects such as anti-inflammatory, antioxidant, anti-atherogenic, hypotensive, lipid-lowering, anti-thrombotic. Moreover, most of medicinal plants are characterized by their pleiotropic anti-atherosclerotic action. In addition, the medicinal plants-derived pharmacological substances and/or compounds are characterized by relative safety and fewer side effects that allows considering them as one of potential anti-atherosclerotic effective agents. The direct anti-atherosclerotic effect of some medicinal plants was confirmed in clinical trials of carotid Intima-media thickness (IMT) progression during long-term medication with medicinal plants. This review attempted to determine the current status of the databases PubMed and Scopus (until November, 2019) to investigate the medicinal plants possessing anti-atherosclerotic activity in experimental and clinical studies.

39 citations

Journal ArticleDOI
TL;DR: Recent evidence on deregulated microRNAs upon pesticide exposure is reviewed, and an overlap between miRNAs deregulated in PD and pesticides is found, as a missing link between the two, to enhance future research in this direction.

39 citations

Journal ArticleDOI
Katrine M Johannesen1, Yuanyuan Liu2, Mahmoud Koko2, Cathrine E Gjerulfsen, Lukas Sonnenberg2, Julian Schubert2, Christina Fenger, Ahmed Eltokhi2, Maert Rannap2, Nils A Koch2, Stephan Lauxmann2, Johanna Krüger2, Josua Kegele2, Laura Canafoglia, Silvana Franceschetti, Thomas U. Mayer, Johannes Rebstock, Pia Zacher, Susanne Ruf3, Michael Alber3, Katalin Sterbova4, Petra Laššuthová4, Marketa Vlckova4, Johannes R. Lemke5, Konrad Platzer5, Ilona Krey5, Constanze Heine5, Dagmar Wieczorek6, Judith Kroell-Seger, Caroline Lund7, Karl Martin Klein8, P Y Billie Au8, Jong M. Rho8, Alice W Ho8, Silvia Masnada3, Pierangelo Veggiotti9, Pierangelo Veggiotti3, Lucio Giordano, Patrizia Accorsi, Christina E. Hoei-Hansen10, Christina E. Hoei-Hansen11, Pasquale Striano12, Federico Zara, Helene Verhelst13, Judith S. Verhoeven14, Bert van der Zwaag15, Aster V. E. Harder15, Eva H. Brilstra15, Manuela Pendziwiat16, Sebastian Lebon17, María Vaccarezza18, Ngoc Minh Le19, Jakob Christensen20, Sabine Grønborg10, Stephen W. Scherer21, Stephen W. Scherer22, Jennifer L. Howe22, Walid Fazeli23, Walid Fazeli24, Katherine B. Howell25, Richard J. Leventer25, Chloe A Stutterd25, Sonja Walsh3, Marion Gérard, Bénédicte Gérard, Sara Matricardi3, Claudia M Bonardi, Stefano Sartori, Andrea Berger, Dorota Hoffman-Zacharska, Massimo Mastrangelo, Francesca Darra26, Arve Vøllo, M. Mahdi Motazacker27, Phillis Lakeman27, Mathilde Nizon, Cornelia Betzler, Cecilia Altuzarra, Roseline Caume, Agathe Roubertie28, Philippe Gelisse28, Carla Marini29, Renzo Guerrini, Frederic Bilan, Daniel Tibussek, Margarete Koch-Hogrebe, M Scott Perry, Shoji Ichikawa, Elena L. Dadali30, A. A. Sharkov30, Irina Mishina, Mikhail Abramov30, Ilya V. Kanivets, Sergey Korostelev31, Sergey Kutsev, Karen E. Wain, Nancy Eisenhauer, Monisa D. Wagner, Juliann M. Savatt, Karen Müller-Schlüter, Haim Bassan32, Artem Borovikov, Marie-Cécile Nassogne33, Anne Destrée, An-Sofie Schoonjans34, Marije Meuwissen34, Marga Buzatu, Anna Jansen35, Emmanuel Scalais36, Siddharth Srivastava3, Wen-Hann Tan3, Heather E. Olson3, Tobias Loddenkemper3, Annapurna Poduri3, Katherine L. Helbig37, Ingo Helbig, Mark Fitzgerald, Ethan M. Goldberg37, Timo Roser38, Ingo Borggraefe38, Tobias Brünger, Patrick May39, Dennis Lal, Damien Lederer, Guido Rubboli11, Henrike O. Heyne, Gaetan Lesca40, Gaetan Lesca41, Ulrike B. S. Hedrich2, Jan Benda2, Elena Gardella1, Holger Lerche2, Rikke S. Møller1 
25 Aug 2021-Brain
TL;DR: In this article, the genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel NaV1.6, were reported.
Abstract: We report detailed functional analyses and genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel NaV1.6, with the aim of describing clinical phenotypes related to functional effects. Six different clinical subgroups could be identified: 1) Benign familial infantile epilepsy (BFIE) (n = 15, normal cognition, treatable seizures), 2) intermediate epilepsy (n = 33, mild ID, partially pharmaco-responsive), 3) developmental and epileptic encephalopathy (DEE, n = 177, severe ID, majority pharmaco-resistant), 4) generalized epilepsy (n = 20, mild to moderate ID, frequently with absence seizures), 5) unclassifiable epilepsy (n = 127), and 6) neurodevelopmental disorder without epilepsy (n = 20, mild to moderate ID). Groups 1-3 presented with focal or multifocal seizures (median age of onset: four months) and focal epileptiform discharges, whereas the onset of seizures in group 4 was later (median: 42 months) with generalized epileptiform discharges. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin-insensitive human NaV1.6 channels and whole-cell patch-clamping. Two variants causing DEE showed a strong gain-of-function (GOF, hyperpolarising shift of steady-state activation, strongly increased neuronal firing rate), and one variant causing BFIE or intermediate epilepsy showed a mild GOF (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (LOF, reduced current amplitudes, depolarising shift of steady-state activation, reduced neuronal firing). Including previous studies, functional effects were known for 170 individuals. All 136 individuals carrying a functionally tested GOF variant had either focal (97, groups 1-3), or unclassifiable epilepsy (39), whereas 34 with a LOF variant had either generalized (14), no (11) or unclassifiable (6) epilepsy; only three had DEE. Computational modeling in the GOF group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. GOF variant carriers responded significantly better to sodium channel blockers (SCBs) than to other anti-seizure medications, and the same applied for all individuals of groups 1-3. In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of LOF variant carriers and the extent of the electrophysiological dysfunction of the GOF variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that SCBs present a treatment option in SCN8A-related focal epilepsy with onset in the first year of life.

38 citations

Journal ArticleDOI
08 Apr 2020
TL;DR: These clinical recommendations present modern ideas about the etiology and pathogenesis of peptic ulcer disease, its clinical manifestations, methods of laboratory and instrumental diagnostics and basic approaches to conservative and surgical treatment.
Abstract: Aim . These clinical recommendations present up-to-date methods for the diagnosis and treatment of peptic ulcer. The recommendations are intended for gastroenterologists and general practitioners. General provisions. Peptic ulcer (PU) represents a chronic relapsing disease occurring with alternating periods of exacerbation and remission. The main manifestation of the disease is the formation of a defect (ulcer) in the wall of the stomach and duodenum. Most cases of peptic ulcer are pathogenetically associated with the infection of H. pylori . PU can be an independent disease or represent symptomatic ulcers of the stomach and duodenum (medicinal, as a result of stress or endocrine pathologies, associated with chronic diseases of internal organs). In the absence of contraindications, esophagogastroduodenoscopy is recommended for all patients with suspected ulcer with the purpose of confirming the diagnosis. In order to determine indications for eradication therapy, all ulcer patients should be tested for the presence of H. pylori using a 13 C-breath test or a stool antigen test. In the case of simultaneous endoscopy, rapid urease test can be used. For the prevention of subsequent relapses of ulcer, all PU patients with confirmed H. pylori should undergo eradication therapy. In addition, in order to achieve ulcer healing, 4–6 week antisecretory therapy with proton pump inhibitors is recommended. Clinical recommendations contain criteria for assessing the quality of medical care, an algorithm of the doctor’s actions, as well as information for patients. Conclusions . These clinical recommendations present modern ideas about the etiology and pathogenesis of peptic ulcer disease, its clinical manifestations, methods of laboratory and instrumental diagnostics and basic approaches to conservative and surgical treatment.

38 citations


Authors

Showing all 8045 results

NameH-indexPapersCitations
Yehuda Shoenfeld125162977195
Jatin P. Shah11972545680
Shahrokh F. Shariat118163758900
Vladimir P. Torchilin10962758977
Klaus-Peter Lesch10652450099
Jürgen Kurths105103862179
Rudolf Valenta10274838349
Valerian E. Kagan9766739888
Hans-Uwe Simon9646151698
Gleb B. Sukhorukov9644035549
Michael Aschner9180632826
Alexei Verkhratsky8945029788
Claudio L. Bassetti8852425332
Helgi B. Schiöth8553128628
Angelo Ravelli7941523439
Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

77% related

Moscow State University
123.3K papers, 1.7M citations

76% related

Russian Academy of Sciences
417.5K papers, 4.5M citations

76% related

Boehringer Ingelheim
14.8K papers, 481.6K citations

75% related

University of Verona
29.9K papers, 968.9K citations

75% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202317
2022102
20212,198
20202,343
20191,649
20181,064